10x Genomics reported first-quarter 2026 revenue of $150.8 million, a 3% decrease from 2025 but a 9% increase excluding one-time license revenue. The company launched Atera, a new spatial whole-transcriptome analysis platform, with shipments expected in the second half of 2026. It also announced a partnership with Bioptimus to create spatial data linking biology to disease outcomes. Despite a net loss of $13.5 million, 10x Genomics ended Q1 with $539.8 million in cash and maintains full-year revenue guidance of $600-$625 million, signaling steady growth ahead.
10x Genomics, a leader in life science technology, will announce its financial results for Q2 ended June 30, 2026, after market close on August 6, 2026. The company will hold a public conference call and live webcast at 1:30 p.m. PT to discuss its ea...
Torex Gold Resources announced positive drilling outcomes at its Morelos Complex, including the ELG Underground and Media Luna Cluster, indicating potential for significant resource expansion and extended mine life. High-grade mineralization was enco...
